Tuesday, March 04, 2025 | 01:03 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Glenmark Pharma gains after USFDA grants for Calcipotriene Cream

The stock opened at Rs 865 on the BSE and touched a high of Rs 873

SI Reporter Mumbai
Shares of Glenmark Pharmaceuticals have risen 1.35% to Rs 869 on the Bombay Stock Exchange (BSE) after Glenmark Pharmaceuticals Inc., USA has been granted final approval by the USFDA for Calcipotriene Cream, 0.005%,

Glenmark Pharmaceuticals said Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Calcipotriene Cream, 0.005%, the therapeutic equivalent of Dovonex Cream, 0.005% of Leo Pharma A/S. Glenmark plans to commence shipping of Calcipotriene Cream, 0.005% immediately.

According to IMS Health sales data, for the 12 month ending April 2015, the Dovonex market achieved annual sales of approximately $91.90 million in the US.
 

The stock opened at Rs 865 on the BSE and touched a high of Rs 873. At 10:42AM, a combined total of 160,000 shares changed hands on the counter of NSE and BSE.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 11 2015 | 10:42 AM IST

Explore News